SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L; Mack, Philip C; Testa, Joseph R; Tsao, Anne S; Wozniak, Antoniette J; Gandara, David R

Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L; Mack, Philip C; Testa, Joseph R; Tsao, Anne S; Wozniak, Antoniette J; Gandara, David R.

Affiliation

Ou SH; *Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, Arizona Cancer Center, University of Arizona Tucson School of Medicine, Tucson, AZ; §Department of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA; âFox Chase Cancer Center, Philadelphia, PA; ¶Department of Medicine, The Universi

J Thorac Oncol ; 10(2): 387-91, 2015 Feb.

Article in En | MEDLINE | ID: mdl-25611229

Subject(s)

Antineoplastic Agents/therapeutic use; Lung Neoplasms/drug therapy; Mesothelioma/drug therapy; Pleural Neoplasms/drug therapy; Sirolimus/analogs & derivatives; Aged; Aged, 80 and over; Disease-Free Survival; Everolimus; Female; Humans; Lung Neoplasms/pathology; Male; Mesothelioma/pathology; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms/pathology; Sirolimus/therapeutic use; TOR Serine-Threonine Kinases/antagonists & inhibitors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Neoplasms / Sirolimus / Lung Neoplasms / Mesothelioma / Antineoplastic Agents Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Thorac Oncol Year: 2015 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google